Acarbose is an effective adjunct to dietary therapy in the treatment of hypertriglyceridaemias

British Journal of Clinical Pharmacology

Volumn 48, Issue 4, 1999, Pages 605-609

  Malaguarnera, M ^a,b   Giugno, I ^a   Ruello, P ^a   Rizzo, M ^a   Motta, M ^a   Mazzoleni, G ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b CANNIZZARO HOSPITAL   (Italy)

Author keywords

Acarbose; Hypertriglyceridaemia; Hypolipaemic drugs

Indexed keywords

ACARBOSE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; MALE; NAUSEA; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ACARBOSE; ADJUVANTS, PHARMACEUTIC; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 0032828756     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00038.x     Document Type: Article

References (24)

1. 1 Puls W, Keup U, Krause HP, Thomas G, Hoffmeister F. Glucosidase inhibition. A new approach to the treatment of diabetes, obesity and hyperlipoproteinaemia. Natunvissenschaften 1977; 64: 563-537.
2. 2 Muller L, Puls W. Pharmacology of alpha-glucosidase inhibitors. In Structure and function of the small intestine ed. Caspary WF. Amsterdam, Excepta Medica 1988: 281-300.
3. 3 Tuomilehto J. Acarbose monotherapy in the treatment of non-insulin-dependent diabetes mellitus-a review. In Acarbose for the Treatment of Diabetes Mellitus. 2nd International Symposium on Acarbose, Berlin, 12-14 November 1987, ed Creutzfeldt W. Berlin, Springer Verlag, 1988: 104-116.
4. 4 Clissold SP, Edwards C. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1988; 35: 214-243.
5. 5 Nestel PJ, Carroll KF, Havenstein N. Plasma triglyceride response to carbohydrates, fats and caloric intake. Metabolism 1970; 19: 1-18.
6. 6 Krause HP, Keup U, Thomas G, Puls W. Reduction of carbohydrate-induced hypertriglyceridaemia in (fa fa) 'Zucker' rats by the α-glucosidase inhibitor acarbose (BAY g5421). Metabolism 1982; 31: 710-714.
7. 7 Zavaroni I, Reaven GM. Inhibition of carbohydrate-induced hypertriglyceridaemia by a disaccharidase inhibitor. Metabolism 1981; 30: 417-420.
8. 8 Leonhardt W, Hamfeld M, Fischer S, Schulze J, Spengler M. Beneficial effects on serum lipids in non-insulin dependent diabetics by acarbose treatment. Drug Res 1991; 41: 435-438.
9. 9 Hillebrand I, Boehme K, Frank G. The effects of the α-glucosidase inhibitor BAY g5421 (acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: Dose-time-response relatioship in man. Res Exp Med (Berl) 1979; 175: 87-94.
10. 10 Homma Y, Irie N, Yano Y, Nakaya N, Goto Y. Changes in plasma lipoprotein levels during medication with a glucosidase-hydrolase inhibitor (acarbose). Tokai J Exp Med 1982; 7: 393-396.
11. 11 Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T. Classification of hyperlipidemias and hyperlipoproteinaemias. Bull Wld Hlth Org 1970; 43: 891-915.
12. 12 Roschlau P, Bernt E, Gruber W. Enzymatische Bestimmung des Gesamtcholesterins in Serum. Chem Klin Biochem 1974; 12: 403-407.
13. 13 Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis: In Methods of Enzymatic Analysis ed. Bergmeyer HU. New York, Academic Press 1974, Vol 4, 1831-1835.
14. 14 McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta 1987; 166: 1-8.
15. 15 Lopez-Virella MF, Stone P, Ellis S, Coltwell JA. Cholesterol determination in high density lipoproteins separated by three different methods. Clin Chem 1977; 23: 882-884.
16. 16 Kesaniemi YA, Grundy SM. Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. Jama 1984; 251: 2241-2246.
17. 17 Kleinman Y, Oschry Y, Eisenberg S. Abnorma regulation of LDL receptor activity and abnormal cellular metabolism of hypertriglyceridemic low density lipoprotein: normalization with bezafibrate therapy. Eur J Clin Invest 1987; 17: 538-543.
18. 18 Sirtori CR, Franceschini G. Effects of fibrates on serum lipids and atherosclerosis. Pharmacol Ther 1988; 37: 167-191.
19. 19 Bakker-Arkema RC, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275: 128-133.
20. 20 Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy people with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989; 320: 202-206.
21. 21 Bischoff H. The mechanism of alpha-glucosidase inhibition in the management of diabetes. Clin Invest Med 1995; 18: 303-311.
22. 22 Malaguarnera M, Giugno I, Puncbianco MP, Pistone G. Beneficial effects of acarbose on familiar hypertriglyceridemias. Clin Pharmacol Ther 1998; 36: 441-445.
23. 23 Baron A, Neumann C. on behalt of the PROTECT Study Group. PROTECT interim results; a large multicenter study of patients with type II diabetes. Clin Ther 1997; 19: 282-295.
24. 14C-acarbose to rats, dogs and man. Arzneimittelforschung/Drug Res 1989; 39: 1254-1260.